Pioglitazone attenuates kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats.
Animals
Anti-Bacterial Agents
/ adverse effects
Catalase
/ metabolism
Creatinine
/ metabolism
Gentamicins
/ adverse effects
Hypoglycemic Agents
/ pharmacology
Kidney
/ drug effects
Kidney Diseases
/ chemically induced
Male
Malondialdehyde
/ metabolism
Oxidative Stress
/ drug effects
Pioglitazone
/ pharmacology
Protective Agents
/ pharmacology
Rats
Rats, Wistar
Superoxide Dismutase
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 09 2019
23 09 2019
Historique:
received:
14
03
2019
accepted:
27
08
2019
entrez:
25
9
2019
pubmed:
25
9
2019
medline:
31
10
2020
Statut:
epublish
Résumé
Gentamicin, belonging to the aminoglycosides, possesses the greatest nephrotoxic effect of all other antibiotics from this group. On the other hand, pioglitazone, which represents peroxisome proliferator-activated receptor γ (PPARγ) agonist recently showed antiinflamatory, antioxidative effects, amelioration of endothelial dysfunction etc. Therefore, the goal of our study was to investigate the effects of pioglitazone on kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats. These effects were observed by following values of biochemical (serum urea and creatinine) parametars, total histological kidney score, urine level of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) as well as parametars of oxidative stress (malondialdehyde, superoxide dismutase, catalase, total oxidant status, total antioxidant status, oxidative stress index and advanced oxidation protein products). It seems that pioglitazone protects the injured rat kidney in a U-shaped manner. Medium dose of pioglitazone (1 mg/kg, i.p.) was protective regarding biochemical (serum urea and creatinine), total histological score and the values of kidney injury molecule-1 (KIM-1) (P < 0.05 vs. control group, i.e. rats injected with gentamicin only). This finding could be of great importance for the wider use of aminoglycosides, with therapy that would reduce the occurrence of serious adverse effects, such as nephrotoxicity and acute renal failure.
Identifiants
pubmed: 31548602
doi: 10.1038/s41598-019-49835-1
pii: 10.1038/s41598-019-49835-1
pmc: PMC6757036
doi:
Substances chimiques
Anti-Bacterial Agents
0
Gentamicins
0
Hypoglycemic Agents
0
Protective Agents
0
Malondialdehyde
4Y8F71G49Q
Creatinine
AYI8EX34EU
Catalase
EC 1.11.1.6
Superoxide Dismutase
EC 1.15.1.1
Pioglitazone
X4OV71U42S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13689Références
Acta Histochem. 2006;108(5):365-71
pubmed: 16999986
Int J Radiat Biol. 1990 Nov;58(5):733-43
pubmed: 1977818
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
ISRN Endocrinol. 2013 May 09;2013:858690
pubmed: 23762597
Cell Physiol Biochem. 2016;38(5):1831-40
pubmed: 27160248
Mol Cell Biochem. 2014 Dec;397(1-2):53-60
pubmed: 25087119
Clin Biochem. 2005 Dec;38(12):1103-11
pubmed: 16214125
Kidney Blood Press Res. 2016;41(6):911-918
pubmed: 27889773
Kidney Int. 1996 May;49(5):1304-13
pubmed: 8731095
Nephrol Dial Transplant. 2000 Aug;15(8):1175-82
pubmed: 10910441
Braz J Med Biol Res. 2017 Dec 11;51(2):e6812
pubmed: 29267505
Mol Cell Biochem. 2016 Jun;417(1-2):111-8
pubmed: 27206738
J Surg Res. 2013 Jun 1;182(1):176-84
pubmed: 22981741
Medicine (Baltimore). 1979 Sep;58(5):362-76
pubmed: 481195
Anal Biochem. 1978 Oct 1;90(1):81-9
pubmed: 727489
Kidney Int. 2006 Oct;70(7):1223-33
pubmed: 16883325
Iran J Med Sci. 2018 Mar;43(2):184-194
pubmed: 29749987
Kidney Int. 2007 Jun;71(12):1232-9
pubmed: 17457378
PLoS One. 2015 Nov 04;10(11):e0142303
pubmed: 26536032
J Biol Chem. 1952 Mar;195(1):133-40
pubmed: 14938361
Sci Pharm. 2014 Aug 18;82(4):709-21
pubmed: 26171320
Clin Biochem. 2004 Apr;37(4):277-85
pubmed: 15003729
J Am Soc Nephrol. 2009 Nov;20(11):2380-8
pubmed: 19797472
Sci Rep. 2016 May 04;6:24392
pubmed: 27142691
Eur J Endocrinol. 2006 May;154(5):613-21
pubmed: 16645006
Am J Physiol Renal Physiol. 2007 Apr;292(4):F1141-50
pubmed: 17190910
Fundam Clin Pharmacol. 2004 Feb;18(1):79-83
pubmed: 14748758
Biol Pharm Bull. 2011;34(5):693-9
pubmed: 21532159
Life Sci. 2007 Feb 27;80(12):1135-42
pubmed: 17234217
Toxicology. 2005 Nov 15;215(3):198-204
pubmed: 16125832
PLoS One. 2014 May 09;9(5):e95313
pubmed: 24816434
J Surg Res. 2013 Oct;184(2):1092-5
pubmed: 23545406
J Chemother. 2010 Apr;22(2):88-91
pubmed: 20435566
Pol J Pharmacol. 2003 Jul-Aug;55(4):631-7
pubmed: 14581723
Lab Invest. 2009 Jan;89(1):47-58
pubmed: 19002105
Nephron Clin Pract. 2009;112(4):c230-41
pubmed: 19546582
J Nephrol. 2005 Sep-Oct;18(5):548-52
pubmed: 16299680
J Physiol Pharmacol. 2018 Apr;69(2):
pubmed: 29980143